# Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT01853644** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 31 (actual)

## Conditions studied

- Recurrent Epithelial Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Recurrent Primary Peritoneal Cancer

## Interventions

- **DRUG:** Tivozanib

## Key facts

- **NCT ID:** NCT01853644
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-06
- **Primary completion:** 2018-10-02
- **Final completion:** 2021-05-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853644, "Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01853644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*